Search Results
Remaining questions on the management of HER2-low breast cancer
Remaining questions surrounding HER2-low breast cancer – how low can you go?
Remaining questions regarding HER2-low breast cancer
Questions remaining in the field of HER2-low breast cancer
Remaining challenges regarding HER2-low breast cancer
Remaining questions on the use of frontline CDK4/6 inhibitors + endocrine therapy
Overview of the management of HER2-low breast cancer patients
Is HER2-low a distinct subtype of breast cancer?
Highlights in HER2-low breast cancer at SABCS 2022
Biological behaviour of HER2-low BC is dependent on HR expression
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis
The evolution of HER2-low breast cancer from primary to recurrence
